Top Markets
#1 Black Phoenix Black Phoenix +826.83%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.73%
#3 Beam Beam +24.43%
#4 Tutorial Tutorial +24.34%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +21.60%
#6 SAFEcoin SAFEcoin +20.63%
#7 Bless Bless +17.83%
#8 THORChain THORChain +16.01%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +15.60%
#10 EfficientFrontier EfficientFrontier +14.37%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Rank in Stocks #5730
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Share Price
$29.86
Last synced: 2026-08-19
Market Cap
$2.48B
Change (1 day)
4.92%
Change (1 year)
502.82%
Country
TW
Trade Lin BioScience, Inc. (6696)

Category

Healthcare
P/E ratio for Lin BioScience, Inc. (6696)
P/E ratio as of 2026 TTM: 0
According to Lin BioScience, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Lin BioScience, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.